Stool-based strategies significantly reduce colonoscopies post-polypectomy.

Stool-based surveillance for individuals with post-polypectomy indications has been shown to safely decrease the need for colonoscopies by 15% to 41%. A study of 3,453 participants found that multitarget stool DNA tests were most effective (AUC 0.72), but also more costly than colonoscopy. In contrast, fecal immunochemical tests were cost-saving. Overall, these strategies could revolutionize colorectal cancer surveillance, significantly reducing patient burden while maintaining effectiveness.